Cargando…

Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy

Lymphocyte depletion chemotherapy CD19-targeted chimeric antigen receptor-modified T (CAR-T) cell immunotherapy is an innovative approach for the treatment of refractory or relapsed B-cell malignancies. This method also has the occurrence of infection, and there has been no systematic analysis of in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Zhilin, Lian, Yu, Ti, Juanjuan, Ren, Ruirui, Ma, Liangming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Clinical Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997630/ https://www.ncbi.nlm.nih.gov/pubmed/36728516 http://dx.doi.org/10.1097/CAD.0000000000001485

Ejemplares similares

Acute intestinal GVHD following donor-derived CD7-CAR-T-cell infusion in a child with Omicron COVID-19
por: Lian, Yu, et al.
Publicado: (2023)

2708. Infectious Complications Among CD19 Chimeric Antigen Receptor T-cell Recipients
por: Huggins, Jonathan, et al.
Publicado: (2023)

Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults
por: Vora, Surabhi B, et al.
Publicado: (2020)

Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

925. Infectious Complications Following Chimeric Antigen Receptor (CAR) T-cell Therapy
por: Trottier, Caitlin, et al.
Publicado: (2021)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
por: Liu, Dongfang, et al.
Publicado: (2020)

1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications
por: Garner, Will, et al.
Publicado: (2020)

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010)

Chimeric antigen receptor T cell: A cancer immunotherapy
por: Singh, Surjit, et al.
Publicado: (2022)

Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy
por: Kravets, Victoria G, et al.
Publicado: (2017)

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
por: Tseng, Hsiang-chi, et al.
Publicado: (2020)

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
por: Zhou, Hui, et al.
Publicado: (2018)

A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
por: Valton, Julien, et al.
Publicado: (2018)

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
por: Kosti, Paris, et al.
Publicado: (2018)

Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer
por: Rahimmanesh, Ilnaz, et al.
Publicado: (2021)

Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
por: Shin, Seungyong, et al.
Publicado: (2023)

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
por: Ying, Zhitao, et al.
Publicado: (2021)

Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
por: Berger, S Carolina, et al.
Publicado: (2014)

Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform
por: Magnani, Chiara F., et al.
Publicado: (2016)

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
por: Zhang, Jianguang, et al.
Publicado: (2019)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2015)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2016)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
por: Budde, Lihua E., et al.
Publicado: (2013)

Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer
por: Dong, Xuhui, et al.
Publicado: (2023)

Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells
por: Maher, John
Publicado: (2012)

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
por: Han, Ethan Q, et al.
Publicado: (2013)

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
por: Mehta, Rohtesh S., et al.
Publicado: (2018)

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
por: Yilmaz, Ahmet, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges
por: Toulouie, Sara, et al.
Publicado: (2021)

Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
por: Brown, Kevin, et al.
Publicado: (2021)

Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
por: Fanciulli, Giuseppe, et al.
Publicado: (2022)

Modern Immunotherapy of Adult B-Lineage Acute Lymphoblastic Leukemia with Monoclonal Antibodies and Chimeric Antigen Receptor Modified T Cells
por: Maino, Elena, et al.
Publicado: (2015)

Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer
por: Li, Ning, et al.
Publicado: (2017)

Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
por: Liu, Dongfang, et al.
Publicado: (2017)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021
por: Ou, Zhanpeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kqsva6ndojg2rtjtp99nb9ehru